Results 101 to 110 of about 602,267 (275)

Cyclic neutropenia [PDF]

open access: yesBritish Dental Journal, 2011
K. Keshwara, Y. Zanganah
openaire   +2 more sources

New anti‐inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)

open access: yesBritish Journal of Pharmacology, EarlyView.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

open access: yesCancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria

open access: yesCancer Science, EarlyView.
Spatial localization of intratumoral bacteria governs their functional roles in tumor progression, metastasis, and treatment responses, with guiding significance for clinical management, as reviewed across three spatial paradigms. ABSTRACT Bacteria in tumors are increasingly recognized to be a part of the tumor microenvironment and their biological ...
Minlan Ren   +11 more
wiley   +1 more source

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

open access: yesCancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka   +15 more
wiley   +1 more source

Application of Spectral Density/Periodogram Analysis to Serial Neutrophil Counts to Diagnose Cyclic Neutropenia

open access: yes
Background: Cyclic neutropenia is characterized by oscillatory fluctuations in blood neutrophil counts, usually with nadirs <0.2 x 109/L at approximately 3 week intervals. Visual inspection of graphs of serial counts is usually the basis for diagnosis.
Dobbins, Nicholas J.   +6 more
core   +1 more source

CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2− Breast Cancer via Lethal ROS and Inhibition of Metastasis

open access: yesCancer Science, EarlyView.
Schematic illustrating that CDK4/6 inhibitors combined with curcumin induce lethal ROS accumulation by disrupting redox balance, downregulating GPX4, and depleting glutathione, leading to DNA damage and lipid peroxidation. This oxidative stress triggers tumor cell death and suppresses EMT‐driven migration.
Chenyu Wang   +14 more
wiley   +1 more source

Testing for Bacteria and Fungi in Cells and Ancillary Reagents—Probe‐Based Quantitative PCR Assays

open access: yesCell Proliferation, EarlyView.
This document specifies the technical elements for bacteria and fungi detection by PCR assay which enables rapid, broad‐spectrum detection of bacteria and fungi with high sensitivity. Qualitative judgement is based on LOD. Key detection points include efficient nucleic acid extraction, broad‐spectrum primer‐probe design, high amplification efficiency ...
Jiani Cao   +25 more
wiley   +1 more source

Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B‐Cell Lymphoma

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy